Your Good Partner in Biology Research

重組蛋白

產(chǎn)品名稱 貨號(hào) 規(guī)格
Recombinant Salmonella enteritidis PT4 Protein slyX (slyX) CSB-YP480819SWO
CSB-EP480819SWO
CSB-BP480819SWO
CSB-MP480819SWO
CSB-EP480819SWO-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Salmonella enteritidis PT4 Ribosomal RNA small subunit methyltransferase C (rsmC) CSB-YP480820SWO
CSB-EP480820SWO
CSB-BP480820SWO
CSB-MP480820SWO
CSB-EP480820SWO-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Salmonella enteritidis PT4 Protein translocase subunit SecA (secA), partial CSB-YP480821SWO
CSB-EP480821SWO
CSB-BP480821SWO
CSB-MP480821SWO
CSB-EP480821SWO-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Salmonella enteritidis PT4 ProP effector (proQ) CSB-YP480822SWO
CSB-EP480822SWO
CSB-BP480822SWO
CSB-MP480822SWO
CSB-EP480822SWO-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Salmonella enteritidis PT4 Na (+)/H (+) antiporter nhaB, partial CSB-YP480823SWO
CSB-EP480823SWO
CSB-BP480823SWO
CSB-MP480823SWO
CSB-EP480823SWO-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Salmonella enteritidis PT4 o-succinylbenzoate synthase (menC) CSB-YP480824SWO
CSB-EP480824SWO
CSB-BP480824SWO
CSB-MP480824SWO
CSB-EP480824SWO-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Salmonella enteritidis PT4 NADH-quinone oxidoreductase subunit K (nuoK), partial CSB-YP480825SWO1
CSB-EP480825SWO1
CSB-BP480825SWO1
CSB-MP480825SWO1
CSB-EP480825SWO1-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Salmonella enteritidis PT4 Ferrous iron transport protein C (feoC) CSB-YP480826SWO
CSB-EP480826SWO
CSB-BP480826SWO
CSB-MP480826SWO
CSB-EP480826SWO-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Salmonella enteritidis PT4 RNA 3'-terminal phosphate cyclase (rtcA) CSB-YP480827SWO
CSB-EP480827SWO
CSB-BP480827SWO
CSB-MP480827SWO
CSB-EP480827SWO-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Salmonella enteritidis PT4 Probable phosphoglycerate mutase GpmB (gpmB) CSB-YP480828SWO
CSB-EP480828SWO
CSB-BP480828SWO
CSB-MP480828SWO
CSB-EP480828SWO-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Salmonella enteritidis PT4 Glutamate-1-semialdehyde 2,1-aminomutase (hemL) CSB-YP480829SWO
CSB-EP480829SWO
CSB-BP480829SWO
CSB-MP480829SWO
CSB-EP480829SWO-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Salmonella enteritidis PT4 Erythronate-4-phosphate dehydrogenase (pdxB) CSB-YP480830SWO
CSB-EP480830SWO
CSB-BP480830SWO
CSB-MP480830SWO
CSB-EP480830SWO-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Salmonella enteritidis PT4 DNA ligase (ligA), partial CSB-YP480831SWO
CSB-EP480831SWO
CSB-BP480831SWO
CSB-MP480831SWO
CSB-EP480831SWO-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Salmonella enteritidis PT4 C4-dicarboxylate transport protein (dctA), partial CSB-YP480832SWO
CSB-EP480832SWO
CSB-BP480832SWO
CSB-MP480832SWO
CSB-EP480832SWO-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Salmonella enteritidis PT4 Proline--tRNA ligase (proS), partial CSB-YP480833SWO
CSB-EP480833SWO
CSB-BP480833SWO
CSB-MP480833SWO
CSB-EP480833SWO-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Salmonella enteritidis PT4 Phosphoribosylaminoimidazole-succinocarboxamide synthase (purC) CSB-YP480834SWO
CSB-EP480834SWO
CSB-BP480834SWO
CSB-MP480834SWO
CSB-EP480834SWO-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Salmonella enteritidis PT4 Glucans biosynthesis protein D (mdoD), partial CSB-YP480835SWO
CSB-EP480835SWO
CSB-BP480835SWO
CSB-MP480835SWO
CSB-EP480835SWO-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Salmonella enteritidis PT4 L-lactate dehydrogenase [cytochrome] (lldD) CSB-YP480836SWO
CSB-EP480836SWO
CSB-BP480836SWO
CSB-MP480836SWO
CSB-EP480836SWO-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Salmonella enteritidis PT4 Phosphopantetheine adenylyltransferase (coaD) CSB-YP480837SWO
CSB-EP480837SWO
CSB-BP480837SWO
CSB-MP480837SWO
CSB-EP480837SWO-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Salmonella enteritidis PT4 Homoserine kinase (thrB) CSB-YP480838SWO
CSB-EP480838SWO
CSB-BP480838SWO
CSB-MP480838SWO
CSB-EP480838SWO-B
20μg/100μg/1mg(1mg*1 or 500ug*2)

有用資源

什么是重組蛋白?

重組蛋白是一種可操縱的蛋白質(zhì)形式,可以通過多種方式產(chǎn)生大量蛋白質(zhì)、修改基因序列和制造有用的商業(yè)產(chǎn)品。重組蛋白的技術(shù)資源在重組蛋白的開發(fā)過程中,除了表達(dá)系統(tǒng)之外,還面臨著一系列令人困惑的選擇,如表達(dá)載體的選擇、表達(dá)蛋白的長度(全長或部分)、是否帶標(biāo)簽等。在生產(chǎn)重組蛋白時(shí),你必須做出很多決定。如果你選擇的明智,你將獲得高質(zhì)量的重組蛋白,后續(xù)的實(shí)驗(yàn)更有可能成功。但是如果你做了錯(cuò)誤的決定,你可能得不到你所需要的重組蛋白或者重組蛋白的質(zhì)量和純度不符合要求。在這里,來自CUSABIO的蛋白表達(dá)工程師根據(jù)他們開發(fā)重組蛋白的經(jīng)驗(yàn)總結(jié)出了幾個(gè)有用的提示,可以幫助你做出明智的決策。

第一條:重組蛋白的生產(chǎn),在這篇文章中,我們旨在闡明重組蛋白的定義以及如何生產(chǎn)重組蛋白。

第二條:如何選擇合適的表達(dá)載體?

表達(dá)載體是一種DNA分子,它攜帶特定的基因進(jìn)入宿主細(xì)胞,并利用細(xì)胞的蛋白質(zhì)合成機(jī)制來產(chǎn)生由該基因編碼的蛋白質(zhì)。表達(dá)載體可使外源基因在宿主細(xì)胞中高效表達(dá),經(jīng)過多年的發(fā)展,表達(dá)載體已成為一種成熟而受歡迎的生物技術(shù)。在重組蛋白生產(chǎn)過程中是一種基本成分。正如標(biāo)題所示,本文主要總結(jié)了幾個(gè)有用的技巧來選擇合適的表達(dá)載體。

第三條:如何表達(dá)具有生物活性的蛋白質(zhì)?

根據(jù)重組蛋白的不同應(yīng)用,對(duì)其生物活性有不同的要求。但是我們?nèi)绾未_保蛋白質(zhì)的產(chǎn)生具有生物活性呢?本文將圍繞這個(gè)主題,并提供一些解決方案。除了以上文章,我們還收集了一些重組蛋白的常見問題。您可以單擊以下鏈接查看。http://m.cstxtech.com/technology-91.html。此外,我們還為我們的客戶提供重組蛋白表達(dá)服務(wù),您可以點(diǎn)擊這里獲取更多信息。注:如果您對(duì)CUSABIO的蛋白質(zhì)有任何疑問,涉及到蛋白質(zhì)的價(jià)格、交貨、質(zhì)量等,您可以點(diǎn)擊橙色按鈕為我們?cè)诰€留言。

引用資料

Recombinant Severe acute respiratory syndrome coronavirus 2 RNA-dependent RNA polymerase(NSP12) cited in "SARS-CoV-2 hijacks cellular kinase CDK2 to promote viral RNA synthesis". Signal transduction and targeted therapy, 2023

Recombinant Mouse Mixed lineage kinase domain-like protein(Mlkl) cited in "OASL phase condensation induces amyloid-like fibrillation of RIPK3 to promote virus-induced necroptosis". Nature cell biology, 2023

Recombinant Mouse Proto-oncogene c-Fos(Fos) cited in "Dihydroartemisinin imposes positive and negative regulation on Treg and plasma cells via direct interaction and activation of c-Fos". Communications biology, 2023

Recombinant Human Keratin, type I cytoskeletal 18(KRT18) cited in "Calcitonin gene-related peptide ameliorates sepsis-induced intestinal injury by suppressing NLRP3 inflammasome activation". International immunopharmacology, 2023

Recombinant Human Protein Wnt-5a (WNT5A) cited in "ATBF1 is a potential diagnostic marker of histological grade and functions via WNT5A in breast cancer". BMC Cancer, 2022

Read More >>